

NOVOGEN LIMITED
ASX: NRT
NASDAQ: NVGN



Market Release

13 March 2014

Novogen to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York

SYDNEY, March 13, 2014 – Novogen Limited (ASX:NRT; NASDAQ:NVGN), an oncology drug development company, today announced that Graham Kelly, Ph.D., Executive Director and Chief Executive Officer, will present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum. Dr. Kelly's presentation will take place at 2:30 p.m. on Wednesday, March 19, 2014 at the New York Academy of Sciences in New York City.

About Novogen Limited

Novogen is a public, Australian biotechnology company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Company is based in Sydney, Australia, and with a U.S. office in New Haven, Connecticut. The Company has two main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs target cancer stem cells and are being developed for the treatment of ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being developed for the treatment of melanoma, prostate cancer and neuroblastoma. Novogen has entered into a joint venture with Yale University known as CanTx Inc. with the aim of developing personalized chemotherapy for patients with ovarian cancer.

Further information is available on the Company's website, www.novogen.com.

For Further Information Contact:

Investors

In the USA

David Carey/Tanner Kaufman
Lazar Partners
+1 212-867-1762
Novogen@lazarpartners.com

In Australia

Rudi Michelson
Monsoon Communications
03 9620 3333
rudim@monsoon.com.au

Media

In the USA

Hollister Hovey/Allison Parks
Lazar Partners
+ 1 212-867-1762
Novogen@lazarpartners.com

In Australia

Dr Douglas Pretsell
Instinctif Partners
+61 (0)3 9657 0706

In ROW

Sue Charles/Stefanie Bacher
Instinctif Partners
+44 (0)20 7457 2020